about
sameAs
Hodgkin's lymphoma, mixed cellularity, involving spleenHodgkin's lymphoma, mixed cellularity, involving lymph nodes of inguinal region and lower limbHodgkin's lymphoma, mixed cellularity, involving lymph nodes of axilla and upper limbHodgkin's lymphoma, mixed cellularity, involving intra-abdominal lymph nodesHodgkin's lymphoma, mixed cellularity, involving intrapelvic lymph nodesHodgkin's lymphoma, mixed cellularity, involving lymph nodes of head, face, and neck
P279
Phase I/II Study of Pentostatin Combined With Tacrolimus and Mini-Methotrexate for GVHD Prevention After MUD BMTRituximab and ABVD for Hodgkin's PatientsA Study of Anti-PD-1 AK105 in Patients With Relapsed or Refractory Classic Hodgkin LymphomaUse of Interim PET Scan to Modify Therapy in Advanced Hodgkin's Lymphoma in Order to Improve OutcomesThe Use of FDG-PET in Patient With Hodgkin Lymphoma: a Population Based Study From Northern ItalyScreening for Coronary Artery Disease After Mediastinal IrradiationPost-transplant Cyclophosphamide and Sirolimus Following Reduced Intensity Conditioning (RIC) TransplantA Safety and Efficacy Study of SB1518 for the Treatment of Advanced Lymphoid MalignanciesSafety and Efficacy Study of PLX3397 in Adults With Relapsed or Refractory Hodgkin LymphomaStudy Comparing ABVD vs BEACOPP in Advanced Hodgkin's LymphomaTandem Auto-Allo Transplant for LymphomaAutologous Transplant in HIV Patients (BMT CTN 0803)Mozobil for Autologous Stem Cell MobilizationReduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic CancersResminostat (4SC-201) in Relapsed or Refractory Hodgkin's LymphomaA Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin's Lymphoma (HL)Unrelated Umbilical Cord Blood (UBC)TransplantationPhase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin LymphomasBMS_PD-L1_onco : Assessment of the PD-L1 Protein as a Biomarker in Oncology and HematologyPrevention of Ovarian Function Damage by a GnRH Analogue During Chemotherapy in Hodgkin Lymphoma PatientsBrentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL)Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT)An Open Label Navigational Investigation of Molecular Profile-Related Evidence Determining Individualized Cancer Therapy for Patients With Incurable Hematologic Malignancies and Poor Prognoses (I-PREDICT Heme)Study of EDO-S101, A First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic MalignanciesSafety of Romiplostim (Nplate®) Following UCBTBrazilian Prospective Hodgkin Lymphoma RegistryPost Transplant Cyclophosphamide (Cytoxan) for GvHD ProphylaxisBendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory LymphomaMeloxicam vs Placebo for MobilizationEarly Markers of Radiation-Induced Cardiac Injury in Hodgkin Lymphoma Treated With Radiation TherapyBrentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVDDose-dense ABVD First Line Therapy in Early Stage Unfavorable Hodgkin's LymphomaBRENTUXIMAB VEDOTIN as Pre-ASCT Induction Therapy in R/R HL Patients Non Responding to IGEVAdcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin LymphomaAssessment of Impact Nutritional Program During Autologous Stem Cell TransplantProspective Study of Lymphoproliferative DiseasesInduction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin LymphomaDonor-Derived Humoral Immunity, Hematopoietic Stem Cell Transplantation, TARCytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALEMusic Therapy on Nausea and Pain for Autologous Stem Cell
P921
Q257331-FCEB5B9B-DDC1-48C6-9726-8E090E791F07Q282629-64767C15-2068-4AA5-8595-F43BD7BD023CQ3950557-611219C2-E511-4956-9270-B28500A6482BQ408524-2A03967D-15ED-40C5-99F0-356328CE22E3Q408524-B04ACCCF-29B8-4127-9593-46287AFB6356Q408977-BACB28AF-3547-40E0-B7FD-3BBFF46E964BQ412415-E0363AFF-6410-4677-A53C-E844D20A0ABDQ415378-B2B7A756-127F-43CD-A94C-DCDAD6DECD6CQ415571-574AFEDA-E843-45F0-B001-0FE7FD5DF49EQ415939-2977AC82-DD7A-40D2-885E-9BE2FE3247F2Q416975-CB3AAA80-96E4-4E6E-9FE4-06361D258106Q418011-01E17137-08B1-4193-BC64-885BB8F2E999Q418560-53B60100-DA40-4800-BB48-AFD230F992FFQ418656-A6ED4332-1BD6-4077-84FE-02295E64C00DQ420532-62088170-813C-4B47-819B-DB65D7FEDEDD
P2175
Q61979856-216F1F07-5717-4DA9-B3E7-021F6F52FA28Q61980067-3E228B97-A245-43B4-BD9F-0CB5E5A5D152Q63598619-7531B286-C237-444C-A5FC-B74DE1194D88Q63813909-7002521B-E96F-4F0E-B5A7-1F1261359771Q63815510-EA1A5CE4-77A4-4B60-8221-703DE524D7F7Q63815856-FA250DEE-9FA0-4EF5-8058-D81ED7B3BDFEQ63815997-68C46611-91B3-44ED-B5EE-3019E19E4906Q63816991-D315B111-CC35-4E80-AB08-706DFF059439Q63818314-0B283039-73FD-4FB7-8B80-C629B52D0983Q63818916-77953178-09E7-4458-906A-2B69B44A81CFQ63828947-B756AD79-6E3B-4B11-9501-11766C20F90DQ63832274-560D623B-3756-4F0F-89C7-CDE2B6AF9601Q63833312-96DD938D-6516-473B-9D70-D4B1877D55EBQ63834036-A8584268-A195-4E34-9B37-579713B54802Q63834786-F4565686-8B2F-4924-9B74-39D97D2FEDAAQ63835909-92C308C9-4479-46B5-90FA-F353E6DB45A5Q63837120-C3A6F6F0-A623-49FB-9332-62EB2E3D21D4Q63837304-7E445E8B-F647-4F7A-B9CF-B315ECB010C5Q63839586-ACA779B0-9A93-474A-BB8D-549D127827DCQ63844973-77866520-97C3-48C7-9AEF-6B0A2C2B1F4DQ64029772-3563B53E-142B-4139-BAC7-CF5BE0B07D42Q64123411-34808A4C-7CBC-4018-B036-B60F4068DA7DQ64149636-18C01C00-7E01-4267-B3F5-F2875ADAF017Q64171555-4CC29583-7433-470C-98D1-2DD0217D1B99Q64173566-526A85A1-7508-4494-ADEC-A4725BF75686Q64217204-883C81E1-108C-4D0A-93A5-6316E8781077Q64223115-CF762DA9-F253-4074-B693-8E28CDF93129Q64335800-65196DE3-3F66-4785-9E54-403325F94362Q64351720-C92A4E9C-A5B3-4A20-8BF9-E07212D260FEQ64393313-90DCB871-51C0-478C-83EA-369E167CB849Q64597901-DBA3F54C-53CE-4783-8461-E13953DA47CFQ64602769-57ABCC25-7E78-422D-B2CE-DF969F0C8793Q64609097-2ADC37F5-A6D8-48CF-83AB-2FFB37A1B979Q64622311-A9634E84-912C-4CC2-831B-5F2886070D52Q64639561-8088E356-6DEE-4C31-807C-26E9722E4E82Q64639829-FB676689-DB29-416F-8598-C4E20ED5D71CQ64644781-0C8D3478-CEA7-408C-AE57-98CE3AD17691Q64645050-FE5BC0A4-303E-45B1-B65E-A345BF150BC3Q64645483-54923796-737A-4D32-94FB-9BB3D9715EF3Q64646668-F03737AE-5D35-42D5-B819-F1DE03AD988E
P921
description
Human disease
@en
مرض يصيب الإنسان
@ar
name
Hodgkin's lymphoma, mixed cellularity
@en
Hodgkins lymfom, blandingstype
@nn
limfoma de Hodgkin amb cel·lularitat mixta
@ca
linfoma de Hodgkin con celularidad mixta
@es
lymffoma Hodgkins, cellogrwydd amrywiol
@cy
lymphome de Hodgkin à cellules mixtes
@fr
لمفوما هودجكين مختلطة الخلوية
@ar
type
label
Hodgkin's lymphoma, mixed cellularity
@en
Hodgkins lymfom, blandingstype
@nn
limfoma de Hodgkin amb cel·lularitat mixta
@ca
linfoma de Hodgkin con celularidad mixta
@es
lymffoma Hodgkins, cellogrwydd amrywiol
@cy
lymphome de Hodgkin à cellules mixtes
@fr
لمفوما هودجكين مختلطة الخلوية
@ar
altLabel
Hodgkin lymphoma, mixed cellularity
@en
Hodgkin's Disease Mixed Cellularity
@en
Hodgkin's Lymphoma Mixed Cellularity
@en
Hodgkin's disease, mixed cellularity (disorder)
@en
Hodgkin's disease, mixed cellularity NOS (disorder)
@en
Hodgkin's disease, mixed cellularity of unspecified site (disorder)
@en
Hodgkin's disease, mixed cellularity of unspecified site
@en
Hodgkin's disease, mixed cellularity
@en
MCCHL
@en
MCHL
@en
prefLabel
Hodgkin's lymphoma, mixed cellularity
@en
Hodgkins lymfom, blandingstype
@nn
limfoma de Hodgkin amb cel·lularitat mixta
@ca
linfoma de Hodgkin con celularidad mixta
@es
lymffoma Hodgkins, cellogrwydd amrywiol
@cy
lymphome de Hodgkin à cellules mixtes
@fr
لمفوما هودجكين مختلطة الخلوية
@ar
P2176
P2888
P1550
P1692
P1748
P1995
P2176
P2892
P31
P4229
P5270
MONDO:0004633
MONDO:0020328